Jounce Therapeutics (Jounce Therapeutics) Additional Paid-In Capital : $476.53 Mil(As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics Additional Paid-In Capital?

Jounce Therapeutics's quarterly additional paid-in capital increased from Jun. 2022 ($471.53 Mil) to Sep. 2022 ($474.09 Mil) and increased from Sep. 2022 ($474.09 Mil) to Dec. 2022 ($476.53 Mil).

Jounce Therapeutics's annual additional paid-in capital increased from Dec. 2020 ($362.27 Mil) to Dec. 2021 ($465.87 Mil) and increased from Dec. 2021 ($465.87 Mil) to Dec. 2022 ($476.53 Mil).

Jounce Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Jounce Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jounce Therapeutics Additional Paid-In Capital Chart

Jounce Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

268.08

281.66

362.27

465.87

476.53

Jounce Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Additional Paid-In Capital	Get a 7-Day Free Trial															465.87	469.05	471.53	474.09	476.53

Jounce Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Jounce Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Jounce Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Jounce Therapeutics (Jounce Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.jouncetx.com

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Executives

Concentra Merger Sub, Inc.	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray	director, officer: CEO and President	22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole	officer: Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu	officer: Chief Medical Officer	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin	officer: CFO and Treasurer	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons	director	C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid	director	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404